Read More Pharma Industry News Seismic Pharmaceuticals begins 600-patient global Phase III study of istaroxime Seismic Pharmaceuticals has enrolled the first patient in its approximately 600-person global RESCUE HF-CS Phase III study of istaroxime, moving a programme with extensive Phase II experience into its pivotal test. byVenkateshSeptember 11, 2026